Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A prognostic index for operable, node-negative breast cancer.

M McCallum1, C Baker, K Gillespie

  • 1Department of Pathology, Victoria Infirmary, South Glasgow University Hospitals NHS Trust, Glasgow, Scotland, UK.

British Journal of Cancer
|May 13, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics of patients with diabetes hospitalised for COVID-19 infection-a brief case series report.

Diabetes research and clinical practice·2020
Same author

Chinese and British Hospitalised Patients with COVID-19-a Comparative Case Series Analysis.

SN comprehensive clinical medicine·2020
Same author

Evaluation of the Stop Smoking Wales NHS Dental Practice Incentive Scheme.

British dental journal·2016
Same author

Exoplanet detection. A terrestrial planet in a ~1-AU orbit around one member of a ~15-AU binary.

Science (New York, N.Y.)·2014
Same author

Pea convicilin: structure and primary sequence of the protein and expression of a gene in the seeds of transgenic tobacco.

Planta·2013
Same author

Donation after cardiac death in non-survivable burns.

Anaesthesia and intensive care·2013

A new prognostic index combining histological grade and specific protein markers accurately predicts breast cancer outcomes in tamoxifen-treated patients. This tool aids in selecting patients for adjuvant chemotherapy, outperforming current guidelines.

Area of Science:

  • Oncology
  • Pathology
  • Pharmacology

Background:

  • Accurate prognostication is crucial for optimizing breast cancer treatment strategies.
  • Identifying reliable markers for predicting treatment response, particularly to endocrine therapy like tamoxifen, remains an area of active research.
  • Existing prognostic tools may not fully capture the heterogeneity of early-stage, node-negative breast cancer.

Purpose of the Study:

  • To develop and validate a prognostic index for predicting long-term outcomes in early-stage, node-negative breast cancer patients.
  • To assess the utility of specific biomarkers (BCL-2, p27, Cyclin D1) in conjunction with histological grade for prognostication.
  • To determine if this index can improve patient selection for adjuvant systemic chemotherapy.

Main Methods:

Related Experiment Videos

  • Retrospective analysis of clinical data and tissue samples from the Scottish Adjuvant Tamoxifen trial.
  • Selection of cases based on distinct outcome categories: >10 years disease-free survival ('good') vs. distant relapse within 6 years ('poor').
  • Calculation and validation of a prognostic index using histological grade and immunohistochemical staining for BCL-2, p27, and Cyclin D1.

    • Main Results:

    • A prognostic index combining histological grade, BCL-2, p27, and Cyclin D1 demonstrated significant predictive power in tamoxifen-treated patients.
    • The index correctly predicted good and poor outcomes in 79% and 74% of cases, respectively (odds ratio 11.0).
    • The index was less effective in patients treated with surgery alone and its performance was limited by tissue specimen age and fixation variability.

    Conclusions:

    • The developed prognostic index offers improved prediction of breast cancer outcomes compared to current international guidelines for tamoxifen-treated patients.
    • This biomarker combination holds potential for refining adjuvant chemotherapy decisions in early-stage breast cancer.
    • Further research may be needed to optimize molecular assay reliability with older tissue samples.